Summit Therapeutics (NASDAQ:SMMT) Price Target Raised to $41.00
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) had its price target increased by equities researchers at The Goldman Sachs Group from $37.00 to $41.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 46.95% […]
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) had its price target increased by equities researchers at The Goldman Sachs Group from $37.00 to $41.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 46.95% […]
